Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)GlobeNewsWire • 05/03/24
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive DifferentiationGlobeNewsWire • 04/29/24
This small-cap stock is expected to take off — if its weight-loss pill trial succeedsMarket Watch • 03/28/24
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichInvestorPlace • 03/25/24
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 03/14/24
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaGlobeNewsWire • 03/11/24
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)GlobeNewsWire • 02/07/24
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming spaceCNBC • 01/17/24
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitGlobeNewsWire • 11/29/23
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive OfficerGlobeNewsWire • 11/27/23
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 11/14/23
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023GlobeNewsWire • 11/13/23
Terns Pharmaceuticals to Participate in Upcoming November Investor ConferencesGlobeNewsWire • 11/09/23
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)GlobeNewsWire • 11/03/23
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid LeukemiaGlobeNewsWire • 10/16/23
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?The Motley Fool • 08/23/23
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 08/08/23